Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Genetic alterations in thyroid cancer mediating both resistance to BRAF inhibition and anaplastic transformation

Oncotarget(2024)10.18632/oncotarget.28544Source: DataRank Database

Genetic alterations in thyroid cancer mediating both resistance to BRAF inhibition and anaplastic transformation is a research paper published in Oncotarget (2024). On theSindex it has a DataRank of 0. It has been cited 9 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access9 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 2.39)OA: goldTopics (51)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (2)

Luc G.T. Morris ORCID,Mark Lee ORCID

Live enrichment

PubMed:38275291 PMC:PMC10812235 OpenAlex:https://openalex.org/W4391161313

NCI NIH HHS

Grant: P30 CA008748

NIDCR NIH HHS

Grant: R01 DE027738

NCI NIH HHS

Grant: F30 CA217184

National Institutes of Health

Grant: 5R01DE027738-04

Identifying and targeting neoantigens in aggressive salivary carcinomas

National Institutes of Health

Grant: 2P30CA008748-43

MOUSE GENETICS

FWCI

2.39

Citation Percentile

0.9%

Citation Trend

2025

2026

goldLicense: cc-by

journalhttps://www.oncotarget.com/article/28544/pdf/

publisherhttps://www.oncotarget.com/article/28544/pdf/

publisherhttps://www.oncotarget.com/lookup/doi/10.18632/oncotarget.28544

journalhttps://doi.org/10.18632/oncotarget.28544

repositoryhttps://pubmed.ncbi.nlm.nih.gov/38275291

Fields of Study

Thyroid Cancer Diagnosis and TreatmentS100 Proteins and AnnexinsMelanoma and MAPK Pathways03 medical and health sciences0302 clinical medicineHumansProto-Oncogene Proteins B-rafPhosphatidylinositol 3-KinasesThyroid NeoplasmsMutationProtein Kinase InhibitorsTOR Serine-Threonine KinasesCell Line, Tumorp120 GTPase Activating Protein

MeSH Terms

HumansMutationThyroid NeoplasmsPhosphatidylinositol 3-Kinasesp120 GTPase Activating ProteinCell Line, TumorProtein Kinase InhibitorsProto-Oncogene Proteins B-rafTOR Serine-Threonine Kinases

Keywords

MedicineCancer researchAnaplastic thyroid cancerCrizotinibPI3K/AKT/mTOR pathwayThyroid cancerNeuroblastoma RAS viral oncogene homologCancerOncologyInternal medicineBiologyLung cancerSignal transductionGeneticsDrug resistanceBraf InhibitorsPik3caAnaplastic TransformationProto-Oncogene Proteins B-rafPhosphatidylinositol 3-KinasesTOR Serine-Threonine KinasesCell Line, TumorResearch PerspectiveMutationHumansp120 GTPase Activating ProteinThyroid NeoplasmsProtein Kinase Inhibitors

Sustainable Development Goals

SDG 0: Good health and well-being